ERBB2 and breast cancer: Second, ERBB3 heterodimerization with ERBB2 has been demonstrated to drive oncogenic signaling in breast cancer [73] as the effects of ERBB2 inhibition could be reversed by increasing ERBB3 phosphorylation and activity to drive a TKI resistance phenotype [72].